3

3.00 (-0.40%)

As of Feb 20, 2024

Equillium, Inc. [EQ]

Source: 

Company Overview

We are a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking, which drives a number of immuno-inflammatory diseases across multiple therapeutic areas. Therefore, we believe itolizumab (EQ001) may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.

CountryUS
Headquartersla jollacalifornia
Phone Number(858) 412-5302
Industrypharmaceutical preparations
CEOBruce D. Steel
Websiteequilliumbio.com